Program
acalabrutinib
Also written as “Acalabrutinib”, “ACP-196” and “Acalabrutinib (ACP-196)”.
Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Mantle-Cell · Lymphoma, Large B-Cell, Diffuse · COVID-19 · Hepatic Insufficiency, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 5220 open or running | phase 4since Jun 11, 2021 | Jan 6, 2014 | Feb 15, 2027phase 3 · NCT02972840 |
| AbbVie | 11 open or running | phase 3since May 20, 2024 | May 20, 2024 | Mar 2028phase 3 · NCT06428019 |
| Ascentage Pharma Group International | 11 open or running | phase 3since Mar 13, 2024 | Mar 13, 2024 | Aug 2027phase 3 · NCT06319456 |
| Ipsen | 10 open or running | phase 2since Dec 29, 2021 | Dec 29, 2021 | none ahead |
Also a collaborator on its studies: Apices Soluciones S.L., Hoffmann-La Roche, Fortrea, eResearch Technology, CISCRP, Parexel, Merck and Eli Lilly.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 37 studies since Jan 6, 2014.
- Apr 28, 20212 phase 1 studiesAstraZeneca · NCT04867980, NCT04867941
- May 5, 20215 phase 1 studiesAstraZeneca · NCT04876807, NCT04901923, NCT04914936 and 2 more
- Jun 11, 2021Phase 4 study in Leukemia, Lymphocytic, Chronic, B-CellAstraZeneca · NCT04930536 · 103 enrolled · India
- Sep 16, 2021Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellAstraZeneca · NCT05057494 · 607 enrolled · United States, Australia, Czechia and more
- Dec 29, 2021Ipsen’s first study: phase 2 study in Hematologic NeoplasmsNew to IpsenIpsen · NCT05205252 · United States
- Jun 5, 2023Phase 2 study in Lymphoma, Mantle-CellAstraZeneca · NCT05951959 · 108 enrolled · United States, Australia, Brazil and more
- Jul 11, 2023Phase 2 study in Lymphoma, Large B-Cell, DiffuseAstraZeneca · NCT05952024 · 80 planned · United States, Brazil, Puerto Rico and more
- Mar 13, 2024Ascentage Pharma Group International’s first study: phase 3 study in CLL/SLLNew to Ascentage Pharma Group InternationalAscentage Pharma Group International · NCT06319456 · 344 planned · China
- May 20, 2024AbbVie’s first study: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNew to AbbVieAbbVie · NCT06428019 · 170 planned · United States, Australia, France and more
- Aug 20, 2024Phase 4 study in Leukemia, B-CellAstraZeneca · NCT06651970 · 60 planned · United States, Czechia, Italy and more
- Jan 21, 2025Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellAstraZeneca · NCT06839872
- May 26, 2025Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellAstraZeneca · NCT07024706 · 80 planned · United States, Austria, Brazil and more
- Jun 12, 2025Phase 2 study in Lymphoma, Mantle-CellAstraZeneca · NCT07029737 · 55 planned · Spain
- Oct 5, 2026Primary completion moved from 2027-01-31 to 2027-04-30Date moved laterphase 3 · +3 months · NCT03836261
Ahead
- Feb 15, 2027Primary completion: phase 3 study in Lymphoma, Mantle-CellAstraZeneca · NCT02972840
- Feb 22, 2027Primary completion: phase 3 study in Lymphoma, Large B-Cell, DiffuseAstraZeneca · NCT04529772
- Apr 30, 2027Primary completion: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellAstraZeneca · NCT03836261
- Jul 15, 2027Primary completion: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellAstraZeneca · NCT05057494
TargetBeta
“An orally available inhibitor of Bruton's tyrosine kinase (BTK) ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor; Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule
Other programs on BTK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ibrutinibrule | Johnson & Johnson | phase 4 | 78 |
| zanubrutinibrule | BeOne Medicines | phase 4 | 35 |
| pirtobrutinibrule | Eli Lilly | phase 4 | 30 |
| ritlecitinibrule | Pfizer | phase 3 | 42 |
| orelabrutinibrule | InnoCare Pharma | phase 3 | 27 |
| rilzabrutinibrule | Sanofi | phase 3 | 23 |
| evobrutinibrule | Merck KGaA, Darmstadt, Germany | phase 3 | 20 |
| fenebrutinib | Hoffmann-La Roche | phase 3 | 18 |
| nemtabrutinib | Merck | phase 3 | 16 |
| rocbrutinibrule | Lupeng Pharmaceutical | phase 3 | 15 |
| tirabrutinibrule | Gilead Sciences | phase 3 | 13 |
| birelentinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
All 55 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07029737Lymphoma, Mantle-Cell · Spain | 2 | Recruiting | AstraZeneca | Dec 31, 2027 | 55 |
| NCT07024706Leukemia, Lymphocytic, Chronic, B-Cell · United States, Austria, Brazil and more | 2 | Recruiting | AstraZeneca | May 1, 2029 | 80 |
| NCT06839872Leukemia, Lymphocytic, Chronic, B-Cell | 2 | Withdrawn | AstraZeneca | Jul 28, 2028 | 0 |
| NCT06651970Leukemia, B-Cell · United States, Czechia, Italy and more | 4 | Recruiting | AstraZeneca | Sep 30, 2032 | 60 |
| NCT06428019Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, France and more | 3 | Recruiting | AbbVie | Mar 2028 | 170 |
| NCT06319456CLL/SLL · China | 3 | Recruiting | Ascentage Pharma Group International | Aug 2027 | 344 |
| NCT05952024Lymphoma, Large B-Cell, Diffuse · United States, Brazil, Puerto Rico and more | 2 | Recruiting | AstraZeneca | Apr 22, 2029 | 80 |
| NCT05951959Lymphoma, Mantle-Cell · United States, Australia, Brazil and more | 2 | Active, not recruiting | AstraZeneca | Oct 31, 2028 | 108 |
| NCT05205252Hematologic Neoplasms · United States | 2 | Withdrawn | Ipsen | Jul 5, 2023 | 0 |
| NCT05057494Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Czechia and more | 3 | Active, not recruiting | AstraZeneca | Jul 15, 2027 | 607 |
| NCT04930536Leukemia, Lymphocytic, Chronic, B-Cell · India | 4 | Completed | AstraZeneca | May 2, 2023 | 103 |
| NCT04905043Healthy Volunteers · United States | 1 | Completed | AstraZeneca | Jul 11, 2016 | 12 |
| NCT04914936Healthy Participants · United States | 1 | Completed | AstraZeneca | Oct 16, 2014 | 72 |
| NCT04898101Healthy Volunteers · United States | 1 | Completed | AstraZeneca | Apr 13, 2016 | 14 |
| NCT04901923Healthy Participants · United States | 1 | Completed | AstraZeneca | May 22, 2014 | 59 |
| NCT04876807Healthy Volunteers · United States | 1 | Completed | AstraZeneca | Mar 15, 2016 | 36 |
| NCT04867980Healthy Volunteers · United States | 1 | Completed | AstraZeneca | May 9, 2016 | 48 |
| NCT04867941Hepatic Insufficiency · United States | 1 | Completed | AstraZeneca | Feb 2, 2015 | 18 |
| NCT04768985Bioequivalence · United States | 1 | Completed | AstraZeneca | May 10, 2021 | 66 |
| NCT04564040Lymphoma, Mantle-Cell · Germany | 1 | Completed | AstraZeneca | Dec 11, 2020 | 20 |
| NCT04529772Lymphoma, Large B-Cell, Diffuse · United States, Australia, Austria and more | 3 | Active, not recruiting | AstraZeneca | Feb 22, 2027 | 611 |
| NCT04489797Communicable Diseases · United States | 1 | Completed | AstraZeneca | Aug 28, 2020 | 35 |
| NCT04497948COVID-19 · Brazil | 1 | Terminated | AstraZeneca | Nov 18, 2020 | 9 |
| NCT04435483Pharmacokinetics · United States | 1 | Completed | AstraZeneca | Jun 26, 2020 | 39 |
| NCT04380688COVID-19 · United States | 2 | Completed | AstraZeneca | Nov 16, 2020 | 62 |
| NCT04346199COVID-19 · Argentina, Brazil, Chile and more | 2 | Completed | AstraZeneca | Nov 17, 2020 | 177 |
| NCT04075292Leukemia, Lymphocytic, Chronic, B-Cell · China, Philippines, Taiwan and more | 3 | Active, not recruiting | AstraZeneca | Jan 3, 2024 | 155 |
| NCT04008706Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Brazil and more | 3 | Completed | AstraZeneca | Nov 4, 2025 | 552 |
| NCT03968848Hepatic Insufficiency · United States | 1 | Completed | AstraZeneca | Mar 13, 2019 | 16 |
| NCT03932331Lymphoma, Mantle-Cell · China | 2 | Active, not recruiting | AstraZeneca | Dec 22, 2022 | 105 |
| NCT03836261Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more | 3 | Active, not recruiting | AstraZeneca | Apr 30, 2027 | 984 |
| NCT03205046DLBCL · United States, United Kingdom | 2 | Terminated | AstraZeneca | Nov 20, 2019 | 25 |
| NCT03198650Part1: Advanced B-cell Malignancies · Japan | 1 | Completed | AstraZeneca | Oct 27, 2022 | 35 |
| NCT02972840Lymphoma, Mantle-Cell · United States, Argentina, Australia and more | 3 | Active, not recruiting | AstraZeneca | Feb 15, 2027 | 635 |
| NCT02970318Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more | 3 | Active, not recruiting | AstraZeneca | Sep 3, 2021 | 310 |
| NCT02735876Lymphoma, Mantle-Cell | 3 | Withdrawn | AstraZeneca | Jun 2020 | 0 |
| NCT02717611Leukemia, Lymphocytic, Chronic, B-Cell · United States, Belgium, France and more | 2 | Active, not recruiting | AstraZeneca | Oct 16, 2020 | 60 |
| NCT02717624Lymphoma, Mantle-Cell · United States, Italy, Poland | 1 | Active, not recruiting | AstraZeneca | Jun 15, 2022 | 72 |
| NCT02586857Glioblastoma · United States | 2 | Active, not recruiting | AstraZeneca | Jun 26, 2020 | 24 |
| NCT02537444Ovarian Neoplasms · United States | 2 | Completed | AstraZeneca | Jul 2018 | 78 |
| NCT02477696Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more | 3 | Active, not recruiting | AstraZeneca | Sep 15, 2020 | 533 |
| NCT02475681Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more | 3 | Completed | AstraZeneca | Feb 8, 2019 | 535 |
| NCT02454179Squamous Cell Carcinoma of Head and Neck · United States | 2 | Completed | AstraZeneca | May 2018 | 78 |
| NCT02448303Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | AstraZeneca | Mar 2018 | 74 |
| NCT02387762Arthritis, Rheumatoid · United States | 2 | Completed | AstraZeneca | May 2016 | 31 |
| NCT02362035Lymphoma, Follicular · United States | 2 | Completed | AstraZeneca | Jul 14, 2020 | 161 |
| NCT02362048Pancreatic Neoplasms · United States | 2 | Completed | AstraZeneca | Mar 2017 | 77 |
| NCT02351739Carcinoma, Transitional Cell · United States | 2 | Completed | AstraZeneca | Feb 2018 | 78 |
| NCT02337829Leukemia, Lymphocytic, Chronic, B-Cell · United States | 2 | Completed | AstraZeneca | Jun 26, 2020 | 48 |
| NCT02213926Lymphoma, Mantle-Cell · United States, Australia, Belgium and more | 2 | Active, not recruiting | AstraZeneca | Dec 4, 2020 | 124 |
| NCT02211014Multiple Myeloma · United States, United Kingdom | 1 | Completed | AstraZeneca | Apr 26, 2019 | 27 |
| NCT02180724Waldenstrom Macroglobulinemia · United States, France, Greece and more | 2 | Active, not recruiting | AstraZeneca | Oct 1, 2019 | 107 |
| NCT02180711Lymphoma, Non-Hodgkin · United States, Canada, Italy | 2 | Active, not recruiting | AstraZeneca | Aug 25, 2023 | 113 |
| NCT02112526Lymphoma, Large B-Cell, Diffuse · United States, United Kingdom | 1 | Completed | AstraZeneca | Jun 30, 2020 | 21 |
| NCT02029443Leukemia, Lymphocytic, Chronic, B-Cell · United States, Italy, United Kingdom | 2 | Active, not recruiting | AstraZeneca | Jul 15, 2021 | 306 |
How it is read
Names in the registry
- “Acalabrutinib”, 28 entries
- “acalabrutinib”, 7 entries
- “ACP-196”, 7 entries
- “Acalabrutinib (ACP-196)”, 3 entries
- “ACP-196 (acalabrutinib)”, 2 entries
Codes read as this program: ACP196.
Conditions, from the studies’ own filings
- Leukemia, Lymphocytic, Chronic, B-Cell, 14 studies
- Lymphoma, Mantle-Cell, 8 studies
- Lymphoma, Large B-Cell, Diffuse, 3 studies
- COVID-19, 3 studies
- Hepatic Insufficiency, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.